Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies

Neuroscience

Volumn 244, Issue , 2013, Pages 77-89

  Verheyen, A ^a   Peeraer, E ^a   Lambrechts, D ^b,c   Poesen, K ^c,d   Carmeliet, P ^c,d   Shibuya, M ^e   Pintelon, I ^f   Timmermans, J P ^f   Nuydens, R ^a   Meert, T ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d Laboratory of Angiogenesis and Neurovascular Link   (Belgium)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Peptide; Peripheral neuropathy; VEGF

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PACLITAXEL; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRESS; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; HYPERGLYCEMIA; IN VITRO STUDY; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL GANGLION; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; GANGLIA, SPINAL; GLUCOSE; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PACLITAXEL; PEPTIDE FRAGMENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84877344678     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.03.050     Document Type: Article

References (39)

1. Apfel S.C. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 1999, 41(Suppl. 1):27-34.
2. Benjamin L.E., Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997, 94:8761-8766.
3. Christianson J.A., Riekhof J.T., Wright D.E. Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice. Exp Neurol 2003, 179:188-199.
4. D'Andrea L.D., Iaccarino G., Fattorusso R., Sorriento D., Carannante C., Capasso D., Trimarco B., Pedone C. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci U S A 2005, 102:14215-14220.
5. Del Bo R., Ghezzi S., Scarpini E., Bresolin N., Comi G.P. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 2009, 283:66-68.
6. Dhondt J., Peeraer E., Verheyen A., Nuydens R., Buysschaert I., Poesen K., Van Geyte K., Beerens M., Shibuya M., Haigh J.J., Meert T., Carmeliet P., Lambrechts D. Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. FASEB J 2011, 25:1461-1473.
7. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
8. Dyck P.J., Peroutka S., Rask C., Burton E., Baker M.K., Lehman K.A., Gillen D.A., Hokanson J.L., O'Brien P.C. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 1997, 48:501-505.
9. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
10. Finetti F., Basile A., Capasso D., Di Gaetano S., Di Stasi R., Pascale M., Turco C.M., Ziche M., Morbidelli L., D'Andrea L.D. Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem Pharmacol 2012, 84:303-311.
11. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273:13313-13316.
12. Hirai A., Yasuda H., Joko M., Maeda T., Kikkawa R. Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neurol Sci 2000, 172:55-62.
13. Kirchmair R., Walter D.H., Ii M., Rittig K., Tietz A.B., Murayama T., Emanueli C., Silver M., Wecker A., Amant C., Schratzberger P., Yoon Y.S., Weber A., Panagiotou E., Rosen K.M., Bahlmann F.H., Adelman L.S., Weinberg D.H., Ropper A.H., Isner J.M., Losordo D.W. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2005, 111:2662-2670.
14. Kirchmair R., Tietz A.B., Panagiotou E., Walter D.H., Silver M., Yoon Y.S., Schratzberger P., Weber A., Kusano K., Weinberg D.H., Ropper A.H., Isner J.M., Losordo D.W. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther 2007, 15:69-75.
15. Knipling L., Wolff J. Direct interaction of Bcl-2 proteins with tubulin. Biochem Biophys Res Commun 2006, 341:433-439.
16. Lauria G., Lombardi R., Borgna M., Penza P., Bianchi R., Savino C., Canta A., Nicolini G., Marmiroli P., Cavaletti G. Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst 2005, 10:202-208.
17. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
18. Malin S.A., Molliver D.C., Koerber H.R., Cornuet P., Frye R., Albers K.M., Davis B.M. Glial cell line-derived neurotrophic factor family members sensitize nociceptors in vitro and produce thermal hyperalgesia in vivo. J Neurosci 2006, 26:8588-8599.
19. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001, 28:131-138.
20. Peeraer E., Van Lutsenborg A., Verheyen A., De Jongh R., Nuydens R., Meert T.F. Pharmacological evaluation of rat dorsal root ganglion neurons as an in vitro model for diabetic neuropathy. J Pain Res 2011, 4:55-65.
21. Ropper A.H., Gorson K.C., Gooch C.L., Weinberg D.H., Pieczek A., Ware J.H., Kershen J., Rogers A., Simovic D., Schratzberger P., Kirchmair R., Losordo D. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009, 65:386-393.
22. Rowinsky E.K. Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 1993, 15:25-37.
23. Ruiz de Almodovar C., Lambrechts D., Mazzone M., Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009, 89:607-648.
24. Santulli G., Ciccarelli M., Palumbo G., Campanile A., Galasso G., Ziaco B., Altobelli G.G., Cimini V., Piscione F., D'Andrea L.D., Pedone C., Trimarco B., Iaccarino G. In vivo properties of the proangiogenic peptide QK. J Transl Med 2009, 7:41.
25. Schratzberger P., Walter D.H., Rittig K., Bahlmann F.H., Pola R., Curry C., Silver M., Krainin J.G., Weinberg D.H., Ropper A.H., Isner J.M. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001, 107:1083-1092.
26. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
27. Shortland P.J., Baytug B., Krzyzanowska A., McMahon S.B., Priestley J.V., Averill S. ATF3 expression in L4 dorsal root ganglion neurons after L5 spinal nerve transection. Eur J Neurosci 2006, 23:365-373.
28. Sondell M., Lundborg G., Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999, 19:5731-5740.
29. Sondell M., Sundler F., Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000, 12:4243-4254.
30. Srinivasan S., Stevens M., Wiley J.W. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000, 49:1932-1938.
31. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H., Van Damme P., Rutten B., Man W.Y., De Mol M., Wyns S., Manka D., Vermeulen K., Van Den Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L., Carmeliet P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005, 8:85-92.
32. Tessler S., Rockwell P., Hicklin D., Cohen T., Levi B.Z., Witte L., Lemischka I.R., Neufeld G. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994, 269:12456-12461.
33. Tschachler E., Reinisch C.M., Mayer C., Paiha K., Lassmann H., Weninger W. Sheet preparations expose the dermal nerve plexus of human skin and render the dermal nerve end organ accessible to extensive analysis. J Invest Dermatol 2004, 122:177-182.
34. Tsujino H., Kondo E., Fukuoka T., Dai Y., Tokunaga A., Miki K., Yonenobu K., Ochi T., Noguchi K. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Mol Cell Neurosci 2000, 15:170-182.
35. Verheyen A., Peeraer E., Nuydens R., Dhondt J., Poesen K., Pintelon I., Daniels A., Timmermans J.-P., Meert T., Carmeliet P., Lambrechts D. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 2012, 135:2629-2641.
36. Wang Y.Q., Cui H.R., Yang S.Z., Sun H.P., Qiu M.H., Feng X.Y., Sun F.Y. VEGF enhance cortical newborn neurons and their neurite development in adult rat brain after cerebral ischemia. Neurochem Int 2009, 55:629-636.
37. Wilson K., Geenen F., Biermans R., Nuydens R., Meert T. Sensory dysfunctions after topical application of cytostatics: a new model for the study of peripheral neuropathies. Int J Neuroprot Neuroregener 2006, 3:31-36.
38. Yasuhara T., Shingo T., Muraoka K., Kameda M., Agari T., Wen Ji Y., Hayase H., Hamada H., Borlongan C.V., Date I. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 2005, 1053:10-18.
39. Ziaco B., Diana D., Capasso D., Palumbo R., Celentano V., Di Stasi R., Fattorusso R., D'Andrea L.D. C-terminal truncation of Vascular Endothelial Growth Factor mimetic helical peptide preserves structural and receptor binding properties. Biochem Biophys Res Commun 2012, 424:290-294.